The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, F.
Right arrow Articles by Flamand, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, F.
Right arrow Articles by Flamand, V.
The Journal of Immunology, 2007, 178: 1301-1311.
Copyright © 2007 by The American Association of Immunologists, Inc.

An Alternative Pathway of NF-{kappa}B Activation Results in Maturation and T Cell Priming Activity of Dendritic Cells Overexpressing a Mutated I{kappa}B{alpha}1

Fabrice Moore*, Sofia Buonocore*, Ezra Aksoy*, Najate Ouled-Haddou*, Stanislas Goriely*, Elena Lazarova*, Frédéric Paulart*, Carlo Heirman{dagger}, Elsy Vaeremans{dagger}, Kris Thielemans{dagger}, Michel Goldman* and Véronique Flamand2,*

* Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium; and {dagger} Laboratory of Physiology, Medical School of Vrije Universiteit, Brussels, Belgium

Maturation of dendritic cells (DC) is a critical step in the induction of T cell responses and depends on the activation of NF-{kappa}B transcription factors. Therefore, inhibition of NF-{kappa}B activation has been proposed as a strategy to maintain DC in an immature stage and to promote immune tolerance. Herein, we generated murine myeloid DC expressing a mutated I{kappa}B{alpha} acting as a superrepressor of the classical NF-{kappa}B pathway (s-rI{kappa}B DC) to investigate the consequences of NF-{kappa}B inhibition on the ability of DC to prime T cell responses. Upon in vitro LPS activation, maturation of s-rI{kappa}B DC was profoundly impaired as indicated by defective up-regulation of MHC class II and costimulatory molecules and reduced secretion of IL-12 p70 and TNF-{alpha}. In contrast, after injection, s-rI{kappa}B DC had the same capacity as control DC to migrate to draining lymph node and to induce Th1- and Th2-type cytokine production in a MHC class II-incompatible host mice. Likewise, s-rI{kappa}B DC pulsed with OVA were as efficient as control DC to induce Ag-specific T cell responses in vivo. Indeed, further in vitro experiments established that s-rI{kappa}B DC undergo efficient maturation upon prolonged contact with activated T cells via the alternative pathway of NF-{kappa}B activation triggered at least partly by lymphotoxin beta receptor ligation and involving processing of p100/RelB complexes.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 The Institute for Medical Immunology is sponsored by the government of the Walloon Region and GlaxoSmithKline Biologicals. This study was also supported by the Fonds National de la Recherche Scientifique (FNRS, Belgium) and an Interuniversity Attraction Pole of the Belgian Federal Science Policy. F.M. is supported by a Formation à la Recherche dans l’Industrie et dans l’Agriculture grant from FNRS, S.B. is a scientific collaborator of the FNRS, S.G. is a postdoctoral fellow of FNRS, and V.F. is a research fellow of FNRS.

2 Address reprint requests to Dr. Véronique Flamand, Institute of Medical Immunology, 8 rue A. Bolland, B-6041 Gosselies, Belgium. E-mail address: vflamand{at}ulb.ac.be

3 Abbreviations used in this paper: DC, dendritic cell; BM-DC, bone marrow-derived DC; Ctrl DC, control-transduced DC; eGFP, enhanced GFP; IKK, I{kappa}B kinase; LN, lymph node; LTbetaR, lymphotoxin beta receptor; Pam3CSK4, S-[2.3-bis(palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys4-OH) trihydrochloride; poly(I:C), polyinosine-polycytidylic acid; s-rI{kappa}B, superrepressor of the classical NF-{kappa}B pathway; WCE, whole cell extract; MEF, mouse embryonic fibroblast; LIGHT, homologous to lymphotoxin, exhibits inducible expression, competes with herpesvirus glycoprotein D for HVEM on T cells.




This article has been cited by other articles:


Home page
J. Immunol.Home page
Z. U. A. Mollah, S. Pai, C. Moore, B. J. O'Sullivan, M. J. Harrison, J. Peng, K. Phillips, J. B. Prins, J. Cardinal, and R. Thomas
Abnormal NF-{kappa}B Function Characterizes Human Type 1 Diabetes Dendritic Cells and Monocytes
J. Immunol., March 1, 2008; 180(5): 3166 - 3175.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
L. E. Summers-deLuca, D. D. McCarthy, B. Cosovic, L. A. Ward, C. C. Lo, S. Scheu, K. Pfeffer, and J. L. Gommerman
Expression of lymphotoxin-{alpha}{beta} on antigen-specific T cells is required for DC function
J. Exp. Med., May 14, 2007; 204(5): 1071 - 1081.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.